Storia in 6 fonti

Stocks fall, pharma firms fret. Indian drug manufacturers sweat over Trump's 100% levy on generics

Trump had announced that non-patented drugmakers would have two years to move production to the US or face a 100% import tariff, which would double a year later.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

hindustantimes.com

timesofindia.indiatimes.com

newsbytesapp.com

theprint.in

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

theprint.inStai leggendo2 g fa

Stocks fall, pharma firms fret. Indian drug manufacturers sweat over Trump's 100% levy on generics

Trump proposed 100% tariffs on generics; Indian pharma (50% of US supply, $10.5B exports) cannot practically relocate in two years. The move disrupts globally integrated supply chains and risks escalating US healthcare costs, signaling reshoring pressure for manufacturing sectors.

originale

Timeline cronologica

mercoledì 22 luglio 2026·economictimes.indiatimes.com
Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%
Trump ⁠has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries.
mercoledì 22 luglio 2026·thehindubusinessline.com
US to impose 100% tariffs on generic medicine imports from Aug 2028
US President Donald Trump on Wednesday announced steep tariffs on imported generic medicines from August 2028, asserting that the move was aimed at onshoring the manufacturing of…

Stocks fall, pharma firms fret. Indian drug manufacturers sweat over Trump's 100% levy on generics

Confronto fonti

Stocks fall, pharma firms fret. Indian drug manufacturers sweat over Trump's 100% levy on generics

Timeline cronologica

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

US to impose 100% tariffs on generic medicine imports from Aug 2028

Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla…

Trump's generic drugs tariff threatens Indian pharma's top market

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

India's pharma sector braces for impact of proposed Trump tariffs on generic drugs

Why these 8 stocks including Pharma majors will remain in focus on today following Trump’s tariff announcement

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028

0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India

Trump threatens tariff on generic medicines: Should India be worried?

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Trump’s proposed generic drug tariffs ‘not practical’, says Indian pharma; US consumers will pay the price

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Pharma stocks decline; Aurobindo Pharma down over 4%

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump’s 100% generic drug duty threatens US low-cost supply

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline